Acute Detection of ST-Elevation Myocardial Infarction Missed on Standard 12-Lead ECG With a Novel 80-Lead Real-Time Digital Body Surface Map: Primary Results From the Multicenter OCCULT MI Trial

James W. Hoekstra, MD
Brian J. O’Neill, MD
Yuri B. Pride, MD
Cedric Lefebvre, MD
Deborah B. Diercks, MD
W. Frank Peacock, MD
Gregory J. Fermann, MD
C. Michael Gibson, MD
Duane Pinto, MD
Jim Giglio, MD
Abhinav Chandra, MD
Charles B. Cairns, MD
Marvin A. Konstam, MD
Joe Massaro, PhD
Mitchell Krucoff, MD

From Wake Forest University, Winston-Salem, NC (Hoekstra, Lefebvre); Wayne State University, Detroit, MI (O’Neill); Beth Israel Deaconess Medical Center, Boston, MA (Pride, Gibson, Pinto); University of California Davis, Sacramento, CA (Diercks); Cleveland Clinic Foundation, Cleveland, OH (Peacock); University of Cincinnati, Cincinnati, OH (Fermann); New York Presbyterian Hospital, New York, NY (Giglio); Duke University Medical Center, Durham, NC (Chandra, Krucoff); University of North Carolina, Chapel Hill, NC (Cairns); Tufts University Medical Center, Boston, MA (Konstam); and Boston University, Boston, MA (Massaro).

Study objective: Although 80-lead ECG body surface mapping is more sensitive for ST-elevation myocardial infarction (STEMI) than the 12-lead ECG, its clinical utility in chest pain in the emergency department (ED) has not been studied. We sought to determine the prevalence, clinical care patterns, and clinical outcomes of patients with STEMI identified on 80-lead but not on 12-lead (80-lead-only STEMI).

Methods: The Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction trial was a multicenter prospective observational study of moderate- to high-risk chest pain patients presenting to the ED. Patients received simultaneous 12-lead and 80-lead ECGs as part of their initial evaluation and were treated according to the standard of care, with clinicians blinded to the 80-lead results. The primary outcome of the trial was door-to-sheath time in patients with 80-lead-only STEMI versus patients with STEMI identified by 12-lead alone (12-lead STEMI). Secondary outcomes included angiographic and clinical outcomes at 30 days.

Results: One thousand eight hundred thirty patients were evaluated, 91 had a discharge diagnosis of 12-lead STEMI, and 25 patients met criteria for 80-lead-only STEMI. Eighty-four of the 91 12-lead STEMI patients underwent cardiac catheterization, with a median door-to-sheath time of 54 minutes, versus 14 of the 25 80-lead-only STEMI patients, with a door-to-sheath time of 1,002 minutes (estimated treatment difference in median = 881; 95% confidence interval 181 to 1,079 minutes). Clinical outcomes and revascularization rates, however, were similar between 80-lead-only STEMI and 12-lead STEMI patients.

Conclusion: The 80-lead ECG provides an incremental 27.5% increase in STEMI detection versus the 12-lead. Patients with 80-lead-only STEMI have adverse outcomes similar to those of 12-lead STEMI patients but are treated with delayed or conservative invasive strategies. [Ann Emerg Med. 2009;54:779-788.]
Acute Detection of ST-Elevation Myocardial Infarction Missed

Editor’s Capsule Summary

What is already known on this topic
The 12-lead ECG does not identify the majority of patients with acute myocardial infarction.

What question this study addressed
Whether patients with ST elevation present on an 80-lead ECG but not on the standard 12-lead ECG behave like ST-elevation myocardial infarction (STEMI) patients.

What this study adds to our knowledge
This study of 1,830 moderate- to high-risk patients suggests that the patients identified with these additional ECG leads have some similarities with traditional STEMI patients.

How this might change clinical practice
It should not change our practice because the study did not assess any intervention that can improve outcome.

SEE EDITORIAL, P. 789.

INTRODUCTION

Background
An estimated 700,000 Americans will experience myocardial infarction, and 500,000 will experience a recurrent myocardial infarction each year.1 For this reason, myocardial infarction has become the focus of aggressive diagnostic and treatment algorithms. Presently, the diagnosis of myocardial infarction is based on several diagnostic tools, including the 12-lead ECG, cardiac biomarkers (troponin), and clinical judgment.2

The 12-lead ECG is the cornerstone in the initial evaluation of chest pain and is especially crucial in the diagnosis of ST-elevation myocardial infarction (STEMI). Unfortunately, the initial 12-lead ECG is not highly sensitive for detection of myocardial infarction when ST-elevation is not present.3-6 It is also severely limited in its detection of right sided, lateral, and posterior myocardial infarction, and it has an especially low sensitivity for myocardial infarction in patients with interventricular conduction delays.7-11 In addition, patients with STEMI that is not identified on 12-lead ECG have been shown to have a poor prognosis.12,13 Improved risk stratification of patients presenting with nondiagnostic 12-lead ECGs and “missed” ST-elevation may lead to improved outcomes.

Eighty-lead ECG body surface mapping is an extension of the conventional 12-lead ECG concept and may deliver improvements to the current diagnostic paradigm for myocardial infarction. The 80-lead displays as a topographic map over a larger area of the thoracic surface, including the right ventricular, posterior, and high left lateral regions. The 80-lead technique allows collection and analysis of data from a broader thoracic area, allowing for greater spatial sampling. The principles of the 80-lead technique have been well established.14-19 With the emergence of more user-friendly computer hardware, software, and electrode application, the 80-lead mapping system has now become feasible in clinical practice for the evaluation of chest pain patients.17-19

Several clinical trials have shown the efficacy of a new generation of 80-lead technology in the detection of myocardial infarction.20-24 In particular, it appears to be well suited for detecting injury patterns in the right ventricular and posterior regions associated with inferior myocardial infarction.23 The enhanced sensitivity of the 80-lead for myocardial infarction and its ease and speed of application should allow the clinician to identify STEMI in ECG-silent areas of the heart within minutes of initial patient contact. This has particular relevance to emergency physicians, who routinely evaluate chest pain patients and are charged with initiating early therapy.

Importance
Patients who are identified as having STEMI by 80-lead but not by 12-lead ECG (referred to as 80-lead-only STEMI patients) have not been previously clinically characterized, especially in a broad emergency department (ED)—based chest pain population. We hypothesize that these 80-lead-only STEMI patients are presently treated in a manner consistent with non-ST-elevation myocardial infarction (NSTEMI) treatment guidelines,2 with either a delayed invasive or selectively invasive angiography approach. This approach is in contrast with the rapid reperfusion strategies used for STEMI patients identified by 12-lead ECG, where door-to-balloon times of 90 minutes or less are advocated.25 We also hypothesize that 80-lead-only STEMI patients have similar angiographic pathology and similar rates of mortality and morbidity (major adverse cardiac events) compared with 12-lead STEMI patients.

Goals of This Investigation
The purpose of this trial is to characterize the prevalence, management patterns, and outcomes of patients with acute coronary syndromes who are identified as having STEMI by 80-lead ECG only with those who are identified as having STEMI by 12-lead ECG to determine whether the potential exists to improve care by early detection of myocardial infarction in these patients.

MATERIALS AND METHODS
Study Design
The Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction trial was a multicenter prospective cohort-blinded observational clinical trial evaluating the 80-lead ECG body surface mapping technology (PRIME ECG; Heartscape, Inc., Columbia, MD) in the care of patients presenting to the ED with chest pain and moderate to high risk for adverse clinical outcomes.
Setting
Patients were enrolled in 12 high-volume tertiary care center EDs in the United States (Appendix E1; available online at http://www.annemergmed.com). The study was approved by the institutional review boards of each site. The study was initiated in November 2006 and concluded in May 2008.

Selection of Participants
Patients were enrolled if they were older than 39 years and presenting to the ED with chest pain or symptoms suspicious for acute coronary syndrome, beginning less than 24 hours before arrival, with the last symptoms less than 12 hours before arrival. Patients had to be moderate to high risk for adverse cardiovascular outcomes, as manifested by chest pain plus ischemic ECG abnormalities, known coronary artery disease, or 3 or more cardiac risk factors (diabetes, hypertension, current smoking, family history of coronary artery disease, or hypercholesterolemia). All patients gave written, informed consent.

Interventions
Patients were evaluated and treated by emergency physicians at each site according to the standard of care. Following their initial ECG, patients were evaluated for eligibility for the study. After informed consent was obtained, the 80-lead ECG body surface mapping system was applied by study personnel or investigators (stipulated to be applied within 20 minutes of the initial ECG). Serial 80-lead ECGs (and simultaneous imbedded 12-lead ECGs) were obtained at the discretion of the treating physician or the study personnel during the following 2 to 4 hours. At least 2 serial 80-lead ECGs per patient were encouraged. The bedside clinical care team was blinded to the 80-lead results but could see the imbedded 12-lead ECG when each serial test was performed.

 Patients were followed during their hospital stay to determine outcomes. Patients who proceeded to coronary angiography were assessed to determine door-to-sheath time (see definitions below). Coronary angiography results were analyzed in a blinded fashion by experienced interventional cardiologists in the Percutaneous/Pharmacologic Endoluminal Revascularization for Unstable Syndromes and its Evaluation (PERFUSE) core lab (TIMI Group, Boston, MA) to determine angiographic outcomes and revascularization rates. Clinical outcomes were recorded by study personnel at the clinical sites and included troponin levels at presentation and prehospitalization, provocative stress testing results, echocardiographic or nuclear perfusion imaging results, and surgical revascularization procedures. Major adverse cardiac events after discharge from the hospital, including death from any cause, recurrent myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting surgery and rehospitalization for coronary complications were assessed at 30 days (see definitions below). Follow-up was obtained by multiple telephone calls, letters, or medical records review. Final diagnoses were obtained from the subject’s discharge summary report.

Eighty-lead and simultaneous 12-lead ECGs were analyzed by the ECG core laboratory at Duke Cardiovascular Research Institute, Durham, NC, by cardiologists and emergency physicians who were blinded to clinical results and the 80-lead mapping system–generated algorithm readings. After elimination of ECGs with bundle branch blocks or technical failures, the 12-lead and 80-lead ECGs were categorized as ischemic (yes/no), and ischemic ECGs were further categorized as ST-elevation, ST-depression, or T-wave changes (Figure 1). ECG location of the ischemic changes was also documented. If serial ECGs were performed on a given patient, only 1 ECG of the series had to be ischemic for that patient to be labeled as “ischemic” by the core laboratory. No historical ECG tracings were available for comparison, unless they were done in serial fashion within the same ED encounter.

Because of the time pressures of reperfusion therapy in patients with STEMI, we found it difficult to enroll STEMI patients in the trial, yet these STEMI patients were crucial to the door-to-sheath time outcome. After enrollment of the first 225 patients, a protocol amendment was implemented to allow patients with 12-lead STEMI to be entered into and proceed within the protocol without undergoing the 80-lead ECG. This amendment yielded a cohort of STEMI patients who were included in the trial but did not undergo 80-lead ECGs. These patients are included in the analysis of the primary and secondary outcomes, but direct comparisons of the performance of the 12-lead to the 80-lead ECG were not possible in this group.

Methods of Measurement
Twelve-lead STEMI was defined by discharge diagnosis, as noted on the discharge summary. NSTEMI was defined by

![Figure 1. ECG core laboratory reading methodology.](image-url)
discharge diagnosis, as noted on the discharge summary. Patients were defined as 80-lead-only STEMI if they were (1) not 12-lead STEMI by discharge diagnosis; (2) had increased troponin levels; (3) had core laboratory–adjudicated 80-lead ECG of STEMI; and (4) had core laboratory–adjudicated 12-lead ECG reading of not STEMI. Twelve-lead NSTEMI patients were defined as NSTEMI by discharge diagnosis after elimination of patients who met criteria for 80-lead-only STEMI. Door-to-sheath time was defined as the time from ED registration to arterial sheath placement in the catheterization laboratory, in minutes. Troponin was reported for blood draws before angiography. Increased troponin level was defined as any increase over the local range of normal at enrolling sites. Troponin levels are reported as either x-fold increases or absolute values in nanograms per milliliter. Death was defined as all-cause mortality within 30 days after discharge from index hospitalization. Recurrent myocardial infarction was defined as rehospitalization within 30 days, with a discharge diagnosis of STEMI or NSTEMI. Rehospitalization was defined as any hospital admission for cardiovascular diagnoses within 30 days from index hospitalization, including discharge diagnosis of myocardial infarction or treatment including percutaneous coronary intervention or coronary artery bypass grafting. Major adverse cardiac events or major adverse clinical events were defined as the combination of death, recurrent myocardial infarction, and rehospitalization. Revascularization was defined as percutaneous coronary intervention or coronary artery bypass grafting after coronary angiography.

Data Collection and Processing
All data were collated and analyzed by Cardiovascular Clinical Trials, Inc., Boston, MA.

Outcome Measures and Primary Data Analysis
The primary outcome of the trial was door-to-sheath time; the primary analysis was the comparison of door-to-sheath time distribution in 80-lead-only STEMI patients versus door-to-sheath time in traditional 12-lead STEMI patients, in only those patients who underwent coronary angiography during their index hospitalization. The comparison was performed with rank analysis of covariance, adjusting for the covariates age, sex, prevalence of diabetes, current smoking status, and histories of hypertension and hypercholesterolemia. A 2-sided significance level of 0.05 was used to declare treatments significantly different.

Angiographic outcomes, including revascularization rates, culprit artery locations, and percentage of stenosis in the culprit artery, were also presented for each group. Revascularization rates were statistically compared between 80-lead-only STEMI and 12-lead STEMI by using odds ratios (ORs) and their 2-sided 95% confidence intervals (CIs). Secondary outcomes of incidence of death, myocardial infarction, and rehospitalization at 30 days were presented for 12-lead STEMI, 80-lead-only STEMI, and 12-lead NSTEMI patients, with 2-sided 95% CIs of the difference between ORs for 80-lead-only STEMI versus 12-lead STEMI and 80-lead-only STEMI versus 12-lead NSTEMI. For dichotomous outcomes in which event rates were large enough, CIs were calculated, adjusting for the same covariates as above; otherwise, CIs were unadjusted. All patients in each group were included, whether or not they underwent coronary angiography. Mean troponin increases and culprit artery stenosis percentages for each group were presented but not compared statistically.

In clinical care, outside of study protocols, the 80-lead ECG is typically not used for patients who have already received a diagnosis of STEMI by 12-lead ECG. The 80-lead ECG offers little clinical value in these patients, and its use may delay reperfusion. On the other hand, it is very useful in patients when the initial 12-lead ECG is nondiagnostic but STEMI is suspected. To assess the incremental value of the 80-lead ECG reading of ST elevation in these patients who were not 12-lead STEMI, the secondary outcomes of incidence of death, myocardial infarction, and death/myocardial infarction at 30 days were analyzed, stratified according to core laboratory–adjudicated 12-lead and 80-lead ECG readings of ST elevation. The strata were as follows: ST-elevation and not ST-elevation by 80-lead ECG, and ST-elevation and not ST-elevation by 12-lead ECG. Unadjusted pairwise ORs between strata and their 2-sided 95% CIs were calculated (multivariate-adjusted ORs were not calculated because of the relatively low event rates in the strata). All analyses were conducted with SAS, version 9.1 (SAS Institute, Inc., Cary, NC).

The following was the planned sample size for the study, with the primary comparison between the 80-lead-only STEMI and the 12-lead STEMI group.26 The sample size was estimated according to a 10% increase in the detection of 80-lead-only STEMI within the NSTEMI group, a 20% incidence of myocardial infarction in the total study population, a 10% dropout rate, and at least a 2.25 times higher median door-to-sheath time in the 80-lead-only STEMI group compared with the 12-lead STEMI group. A sample size of 1,400 patients or 280 myocardial infarctions was chosen to provide at least 80% power to detect a significant difference in the door-to-sheath time distribution between 80-lead-only STEMI and 12-lead STEMI at a 2-sided alpha of 0.05, under these assumptions.

The final sample size was increased to 1,800 patients according to a blinded interim analysis by the study data safety and monitoring board. Specifically, the event rate (myocardial infarction) was lower than initially estimated, necessitating the addition of 400 patients to the sample size to attain the appropriate number of 80-lead-only STEMI patients.

RESULTS
Characteristics of Study Subjects
There were 1,830 patients enrolled in the trial, 1,829 of whom had diagnoses assigned. Of these, 91 patients received a
diagnosis of STEMI by the treating physicians using the 12-lead ECG only (designated 12-lead STEMI, Figure 2), whereas 132 received a diagnosis of NSTEMI and 1,607 as unstable angina, acute coronary syndrome, or other chest pain diagnoses.

Twenty-five patients met criteria for 80-lead-only STEMI. Twelve of these patients came from the NSTEMI diagnosis group, and 13 had received a diagnosis of unstable angina or acute coronary syndrome. We found that the discharge diagnoses of unstable angina or acute coronary syndrome were quite variable, and that many of the patients receiving a diagnosis by clinicians of unstable angina or acute coronary syndrome had an increased troponin level. Thirteen of the patients had increased troponin levels and ST elevation results on their 80-lead ECG and thus met criteria for 80-lead-only STEMI. Twenty-five patients met criteria for 80-lead-only STEMI. One hundred twenty patients who received a discharge diagnosis of NSTEMI did not meet core laboratory–adjudicated criteria for 80-lead-only STEMI.

One hundred twenty patients who received a discharge diagnosis of NSTEMI in Figure 2). Baseline characteristics between all three groups (STEMI, 12-lead NSTEMI, and 80-lead-only STEMI) are shown in Table 1.

Main Results

Of the 91 patients with 12-lead STEMI, 84 (92.3%) underwent cardiac catheterization; of the 25 patients with 80-lead-only STEMI, 14 (56.0%) underwent cardiac catheterization (80-lead-only versus 12-lead OR 0.1; 95% CI 0.04 to 0.4). Among patients who underwent cardiac catheterization, the median door-to-sheath time was significantly shorter among 12-lead STEMI (54.0 minutes) than 80-lead-only STEMI patients (1,002.5 minutes) (Hodges-Lehman estimate of treatment difference in median = 881; 95% CI 181 to 1,079 minutes) (Table 2).

Eighty-eighty-only STEMI patients undergoing cardiac catheterization had rates of revascularization (percutaneous coronary intervention or coronary artery bypass grafting) similar to those of 12-lead STEMI patients undergoing cardiac catheterization (12/14 [85.7%] versus 79/83 [95.2%]; OR 0.6; 95% CI 0.3 to 1.8). One 12-lead STEMI patient had missing revascularization information. Angiographic outcomes in the 80-lead-only STEMI patients are shown in Table 3.

Clinical outcomes were evaluated among all patients with 12-lead STEMI, 80-lead-only STEMI, and 12-lead NSTEMI, regardless of whether they underwent cardiac catheterization. Eighty-eight-only STEMI patients had 30-day rates of death, recurrent myocardial infarction, and rehospitalization for cardiovascular reasons similar to those of patients with 12-lead STEMI (Table 4). In addition, 80-lead-only STEMI patients had 30-day rates of death, myocardial infarction, and rehospitalization that were descriptively higher than but statistically similar to those of patients with 12-lead NSTEMI (Table 4). Mean peak troponin levels and culprit lesion angiographic stenosis percentages for 12-lead STEMI, 80-lead-only STEMI, and 12-lead NSTEMI groups are shown in Table 5.

The 25 patients identified as 80-lead-only STEMI constituted a 27.5% increase in the number of patients identified with STEMI over the 91 patients identified as 12-lead STEMI by the treating physician (4.9% of the cohort had 12-lead STEMI versus 6.3% with 12-lead STEMI plus 80-lead-only STEMI). They also represented 1.4% of the overall study population and 10.4% of those patients (n = 241) with increased cardiac biomarker levels but without a diagnosis of 12-lead STEMI.

To further explore the incremental value of the 80-lead ECG, we compared the rates of troponin positivity, death, and recurrent myocardial infarction for patients with and without a reading of ST-elevation by 80-lead ECG, excluding those patients receiving a diagnosis of 12-lead STEMI by the treating physician. Outcomes among patients not receiving a diagnosis of 12-lead STEMI by the treating physician (n = 1,739) were assessed according to the ECG core laboratory definitions of ST elevation or no ST elevation. Two hundred twenty-five patients were eliminated because of insufficient data or inevaluable ECGs (left bundle branch block or technical failures). In the remaining 1,514 patients with available outcome data, an 80-lead reading of ST elevation was associated with a statistically higher rate of death (OR 11.2; 95% CI 1.8 to 67) and a strong trend toward a higher rate of death and recurrent myocardial infarction (OR 3.4; 95% CI 1.0 to 11) than those of patients without a reading of ST-elevation on 80-lead (Table 6). ST elevation on the 12-lead ECG, however, was not predictive of adverse outcomes in this population. LIMITATIONS

There are limitations to our study that deserve mention. The sample size of 80-lead-only STEMI patients was relatively small. Our study was sufficiently powered to detect a difference in door-to-sheath time, but it was not sufficiently powered to detect differences in clinical outcomes. Conclusions about clinical and angiographic outcomes must take this into account. We chose to analyze relatively gross process differences (such as...
door-to-sheath time) and catheterization outcomes (such as revascularization rates) in our study. Other variables in treatment, such as medications, patient disposition, and physician practice variables, may have affected the patient outcomes but were not analyzed in our study.

Second, the inability to perform 80-lead ECGs in 68 of 91 12-lead STEMI patients because of logistic issues and consent issues with rapid reperfusion makes it difficult to do formal sensitivity/specificity analysis of the 80-lead versus the 12-lead ECG in STEMI, which is regrettable but could not be avoided. We chose to substitute an incremental value analysis rather than sensitivity/specificity analysis for this reason. Formal sensitivity/specificity analysis of the 80-lead ECG for myocardial infarction has been reported elsewhere.19-24

Third, all patients with left bundle branch block or right bundle branch block were classified as having technical failure by the core laboratory. Of the 1,830 subjects, 135 were eliminated because of inadequate ECG tracings or bundle

door-to-sheath time and catheterization outcomes (such as revascularization rates) in our study. Other variables in treatment, such as medications, patient disposition, and physician practice variables, may have affected the patient outcomes but were not analyzed in our study.

Second, the inability to perform 80-lead ECGs in 68 of 91 12-lead STEMI patients because of logistic issues and consent issues with rapid reperfusion makes it difficult to do formal sensitivity/specificity analysis of the 80-lead versus the 12-lead

Table 1. Demographics of 12-lead STEMI, 80-only STEMI, and 12-lead NSTEMI groups.

<table>
<thead>
<tr>
<th>Demographic</th>
<th>12-Lead STEMI N=91</th>
<th>80-Lead STEMI N=25</th>
<th>12-Lead NSTEMI N=120</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y, mean (SD)</td>
<td>63.8 (13.0)</td>
<td>66.4 (13.2)</td>
<td>63.6 (12.3)</td>
</tr>
<tr>
<td>Male, No. (%)</td>
<td>55 (60)</td>
<td>17 (68)</td>
<td>84 (70)</td>
</tr>
<tr>
<td>Diabetes, No. (%)</td>
<td>26 (29)</td>
<td>10 (40)</td>
<td>46 (38)</td>
</tr>
<tr>
<td>Hypertension, No. (%)</td>
<td>52 (57)</td>
<td>22 (88)</td>
<td>100 (83)</td>
</tr>
<tr>
<td>Hypercholesterol, No.%( )</td>
<td>53 (58)</td>
<td>18 (72)</td>
<td>80 (67)</td>
</tr>
<tr>
<td>Smoker, No. (%)</td>
<td>28 (31)</td>
<td>8 (32)</td>
<td>37 (31)</td>
</tr>
</tbody>
</table>

Table 2. Angiographic outcomes, 12-lead STEMI versus 80-only STEMI.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>12-Lead STEMI</th>
<th>80-Lead Only STEMI</th>
<th>Effect Size* (2-Sided 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Door-to-sheath time, median (IQR), min</td>
<td>54.0 (30-112)</td>
<td>1,002.5 (229-1626)</td>
<td>881 (181-1079)</td>
</tr>
<tr>
<td>With angiogram, %</td>
<td>92.3 (84/91)</td>
<td>56 (14/25)</td>
<td>0.1 (0.04-0.4)</td>
</tr>
<tr>
<td>Revascularization, %</td>
<td>95.2 (79/83)</td>
<td>85.7 (12/14)</td>
<td>0.3 (0.1-1.8)</td>
</tr>
</tbody>
</table>

*Effect size is Hodges-Lehmann treatment difference in median for door-to-sheath time (calculated as 80L minus 12L) and OR for remaining characteristics (calculated as 80L/12L).

Table 3. Angiographic outcomes: 80-only STEMI patients.

<table>
<thead>
<tr>
<th>Patient #</th>
<th>DTST, min</th>
<th>Peak TnI, x-fold elev</th>
<th>Culprit Artery</th>
<th>TIMI Flow</th>
<th>% Occlusion</th>
<th>Revasc</th>
<th>80-Lead ECG Ischemia Location</th>
<th>Final Dx</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>110</td>
<td>59</td>
<td>LCX</td>
<td>0</td>
<td>100</td>
<td>Yes</td>
<td>Posterior</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>2</td>
<td>132</td>
<td>215</td>
<td>RCA</td>
<td>3</td>
<td>80</td>
<td>Yes</td>
<td>Ant/Right</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>3</td>
<td>161</td>
<td>97</td>
<td>SVG to RCA</td>
<td>3</td>
<td>90</td>
<td>Yes</td>
<td>Right</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>4</td>
<td>229</td>
<td>28</td>
<td>RCA</td>
<td>0</td>
<td>100</td>
<td>Yes</td>
<td>Right</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>5</td>
<td>252</td>
<td>1095</td>
<td>NA</td>
<td>0</td>
<td>NA</td>
<td>Yes</td>
<td>Right/Post</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>6</td>
<td>462</td>
<td>186</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Yes</td>
<td>Right/Post</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>7</td>
<td>972</td>
<td>3.8</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>Ant/ lateral</td>
<td>ACS</td>
</tr>
<tr>
<td>8</td>
<td>1,087</td>
<td>2.7</td>
<td>SVG to RCA</td>
<td>3</td>
<td>95</td>
<td>Yes</td>
<td>Right</td>
<td>ACS</td>
</tr>
<tr>
<td>9</td>
<td>1,626</td>
<td>18</td>
<td>Multiple</td>
<td>0</td>
<td>NA</td>
<td>Yes</td>
<td>Posterior</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>10</td>
<td>3,209</td>
<td>2.1</td>
<td>SVG To RCA</td>
<td>3</td>
<td>95</td>
<td>Yes</td>
<td>Right</td>
<td>ACS</td>
</tr>
<tr>
<td>11</td>
<td>4,165</td>
<td>34</td>
<td>Multiple</td>
<td>3</td>
<td>NA</td>
<td>Yes</td>
<td>Ant/Lat</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>12</td>
<td>1,033</td>
<td>31</td>
<td>LAD</td>
<td>3</td>
<td>85</td>
<td>Yes</td>
<td>Inf/Ant/Lat</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>13</td>
<td>1,588</td>
<td>5.9</td>
<td>RCA</td>
<td>0</td>
<td>100</td>
<td>Yes</td>
<td>Right</td>
<td>NSTEMI</td>
</tr>
<tr>
<td>14</td>
<td>2,753</td>
<td>1.0</td>
<td>LAD</td>
<td>3</td>
<td>50</td>
<td>No</td>
<td>Ant/Lat</td>
<td>Other</td>
</tr>
</tbody>
</table>

DTST, Door-to-sheath time; TnI, troponin I; TIMI Flow, thrombolysis in myocardial infarction flow rate.

Table 4. Clinical outcomes in 12-lead STEMI versus 80-only STEMI versus 12-lead NSTEMI patients.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>12-Lead STEMI, %, n=91</th>
<th>80-Only STEMI, %, n=25</th>
<th>12-Lead NSTEMI, %, n=120</th>
<th>OR (2-Sided 95% CI) 80-Lead/12-Lead</th>
<th>OR (2-Sided 95% CI) 80-Lead/NSTEMI</th>
</tr>
</thead>
<tbody>
<tr>
<td>MACE (D, MI, Rehosp)</td>
<td>10.2 (9/88)</td>
<td>12 (3/24)</td>
<td>7.0 (8/115)</td>
<td>1.5 (0.3-7.3)</td>
<td>1.8 (0.4-7.5)</td>
</tr>
<tr>
<td>Death</td>
<td>4.6 (4/88)</td>
<td>8 (2/24)</td>
<td>0.9 (1/115)</td>
<td>1.9 (0.3-11)</td>
<td>10.4 (0.9-120)</td>
</tr>
<tr>
<td>MI</td>
<td>3.5 (3/87)</td>
<td>4 (1/24)</td>
<td>5.3 (6/114)</td>
<td>1.2 (0.1-12)</td>
<td>0.8 (0.1-6.7)</td>
</tr>
<tr>
<td>Rehospitalization</td>
<td>5.8 (5/87)</td>
<td>0 (0/24)</td>
<td>5.3 (6/114)</td>
<td>N/A*</td>
<td>N/A*</td>
</tr>
</tbody>
</table>

MACE, Major adverse cardiac events; MI, Myocardial infarction.
*OR CI not estimable because of 0 rehospitalizations in the 80L group.
The patients in the Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction clinical trial may not have perfectly mirrored the optimum patient characteristics for clinical utilization patterns of the 80-lead ECG in "real practice." The treating clinician was blinded to the results of the 80-lead ECG. As such, the treating clinician may not have ordered the 80-lead in real life or intended to use the 80-lead in his or her clinical decisionmaking.

This study did not analyze the cost-effectiveness of the 80-lead ECG. Cost-effectiveness will be analyzed in a separate article. We analyzed only the positive predictive ability of the 80-lead ECG to detect 80-lead-only STEMI. Each 80-lead vest costs approximately $160, and using the 80-lead ECG in 1,830 patients to detect 25 80-lead-only STEMI patients would not be cost-effective. This article does not analyze the predictive value of the 80-lead ECG for NSTEMI or acute coronary syndrome, nor does it analyze the negative predictive value of a normal 80-lead ECG. To assess the cost-effectiveness of the 80-lead ECG, all these effects need to be analyzed together, which will be reported elsewhere.

**DISCUSSION**

The purpose of this study was to characterize the prevalence, management patterns, and outcomes of patients with acute coronary syndromes who are identified as having STEMI by 80-lead ECG only versus those who are identified as having STEMI by 12-lead ECG, to determine whether the potential exists to improve care by speeding the diagnosis of STEMI in these patients. We were able to detect 25 patients in our study with study-defined 80-lead-only STEMI versus 91 patients receiving a diagnosis by clinicians of 12-lead STEMI and 120 receiving a diagnosis by clinicians of 12-lead NSTEMI. The 25 patients with 80-lead-only STEMI had significantly longer
door-to-sheath time than 12-lead STEMI patients and were treated with a significantly delayed and conservative cardiac catheterization strategy. Their angiographic and clinical outcomes, however, were very similar to those of 12-lead STEMI patients.

Our study results are consistent with past clinical studies of the 80-lead ECG body surface mapping technology, but with the largest and most risk-diverse population studied to date, to our knowledge. The 80-lead ECG has never been studied in an undiagnosed ED chest pain population before this study. Several clinical trials have shown the efficacy of 80-lead technology in the detection of myocardial infarction in high-risk patients only.20–24 Menown et al20 prospectively evaluated validation-set chest pain patients whose initial 12-lead ECG showed ST depression only. They demonstrated sensitivity for myocardial infarction in a 12-lead multivariate ECG model of 38% and specificity 81% versus sensitivity by the 80-lead ECG of 88% and specificity 75%. The 80-lead ECG has also displayed the potential for early detection of STEMI in specific regions of the myocardium. In particular, it appears to be well suited for detecting injury patterns in the right ventricular and posterior regions associated with inferior myocardial infarction.23 This was also demonstrated by Ornato et al,21 whose multicenter trial compared the 80-lead to 12-lead ECG in detecting STEMI among patients with biomarker-confirmed myocardial infarction and a discharge diagnosis of myocardial infarction. The 80-lead ECG showed a 26% greater sensitivity than the 12-lead ECG for identifying ST elevation, whereas specificity between the 2 diagnostic modalities was comparable.21 Our study, consistent with previous studies, showed a 27.5% relative increase in STEMI detection with the 80-lead ECG over the 12 lead.

The standard 12-lead ECG is not optimally effective in detecting STEMI in patients with infarcts in the posterior, right, inferior, and high lateral areas of the heart.7–11 Conversely, the 80-lead ECG is more sensitive for detecting STEMI in these areas.18–24 As would be expected, the 80-lead-only STEMI patients in our study demonstrated ST elevation most commonly in the right and posterior regions. At angiogram, they demonstrated involvement most often in the posterior (left circumflex artery) and inferior (right coronary artery) arterial distributions. The culprit arteries at angiogram had high-grade stenoses in the majority of cases, and their arterial distribution also correlated nicely with the areas of ST elevation on the 80-lead ECGs. In addition, as demonstrated in Table 5, the culprit artery stenosis percentage at coronary angiogram in the 80-lead-only STEMI patients also closely resembled that of the 12-lead STEMI patients more than that of the 12-lead NSTEMI patients.

Although our study was not sufficiently powered to demonstrate differences in clinical outcomes, the death, myocardial infarction, and rehospitalization rate in the 80-lead-only STEMI population was very similar to that seen in the 12-lead STEMI population and trended worse than outcomes in 12-lead NSTEMI patients. This is also consistent with past studies that demonstrated similar or worse outcomes for patients with angiographically defined STEMI.12,13 A recent analysis of the NSTEMI patients in the trial had angiographic findings consistent with STEMI (single culprit lesion with thrombolysis in myocardial infarction flow rates (TIMI) 0/1 flow). In the study, NSTEMI patients with high-grade stenoses at angiogram had significantly higher 6-month mortality (OR 1.72; 95% CI 1.07 to 2.79) than NSTEMI patients with traditional “open arteries” observed at angiogram. In a retrospective review of the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel, 26.2% of the 1,198 patients presenting with isolated anterior depression13 had a low TIMI flow grade of 0/1 during angiography and a positive troponin level result and were classified as “STEMI.” The 30-day death or myocardial infarction rate for the STEMI patients was 8.6% compared with 6.3% for NSTEMI and 2.9% for unstable angina (3-way p = 0.006). Our results demonstrated a 12.5% 30-day death, myocardial infarction, and rehospitalization rate in the 80-lead-only STEMI patients, which was the highest of the 3 diagnostic groups, although not statistically so. In addition, peak preangiogram troponin levels trended higher in 80-lead-only STEMI versus NSTEMI patients as well, although they were not statistically analyzed. These results are consistent with the findings in past studies reporting that patients with missed STEMI are at high risk for adverse outcomes.12,13,27

The treatment patterns demonstrated in this study for 80-lead-only STEMI patients are also consistent with past studies. In the study by Gibson et al13 of 1,198 patients with acute coronary syndrome and isolated anterior ST depression, only 5% received a diagnosis by treating physicians of STEMI, and none received coronary angiogram within 6 hours. The median time to catheterization was 29 hours in this study, consistent with a classic NSTEMI management strategy.2,28 Clinicians are presumably reluctant to use an aggressive “time is muscle” catheterization approach in patients without STEMI on their initial 12-lead ECG, and at this point the data from past studies do not support such an approach. Our study, in conjunction with the Gibson et al13 and Wang et al12 studies, indicates that there may be a population of “missed STEMI” patients who are at high risk for adverse outcomes and may benefit from early, more aggressive catheterization if they can be identified by 80-lead ECG.

Because 68 of the 91 STEMI patients in our study did not undergo 80-lead ECG analysis, we were unable to perform traditional sensitivity/specificity analysis of the 80-lead ECG versus the 12-lead ECG for either STEMI or troponin-increased myocardial infarction. We chose instead to analyze the incremental value of the 80-lead ECG after eliminating all patients with the discharge diagnosis of STEMI. This is
consistent with clinical use of the 80-lead ECG in the ED. The 80-lead ECG is useful for the detection of ischemic changes in high-risk chest pain patients after an initial 12-lead ECG result is either negative or nondiagnostic for STEMI. As such, we analyzed the predictive value of the 80-lead versus the 12-lead ECG for death, myocardial infarction, and troponin positivity in all patients who were not 12-lead STEMI. In our study, an 80-lead reading of ST elevation in these traditional NSTEMI patients was much more predictive of death and myocardial infarction than a reading of ST-elevation on the 12-lead ECG. Both tests predicted troponin increase well. However, our study was not powered for clinical outcomes, and these results, although consistent with those of past studies, are limited by the small study population. There will always be false-positive 80-lead ECGs for STEMI, and there will always be false-positive 12-lead ECGs for STEMI, but past studies have shown that the specificity of a reading of ST elevation on the 80-lead or 12-lead ECG is similar and high for myocardial infarction. Any ECG reading must be correlated to the clinical picture. Our study indicates that once data for patients with 12-lead STEMI are eliminated, a reading of ST elevation on the 80-lead ECG is much more predictive of adverse outcomes than a similar reading on the 12-lead ECG.

In our study, the 80-lead ECG body surface mapping system provided an incremental 27.5% increase in STEMI detection versus the 12-lead ECG. These patients with 80-lead-only STEMI are presently treated with a significantly delayed and conservative cardiac catheterization strategy, yet they have angiographic and clinical adverse outcomes similar to those of STEMI patients, detected by 12-lead ECG. These patients may have a potential for improved care and early intervention with early STEMI detection using the 80-lead ECG. Finally, in the patient without STEMI by 12-lead ECG, the incremental value of an 80-lead ECG reading of ST-elevation is significantly more predictive of adverse cardiovascular outcomes than a similar reading on the 12-lead ECG alone.

**Supervising editor:** Judd E. Hollander, MD

**Author contributions:** JWH and MK were the co–principal investigators. JWH was responsible for primary article preparation. JWH, JG, MAK, and MK were responsible for study design. BJO, CL, DD, GJF, and AC were the site principal investigators. BJO, CL, DD, and JG enrolled patients. BJO, JG, and MAK were members of the steering committee. BJO, YP, CD, DD, WFP, GJF, CMG, DP, MAK, and MK were responsible for article editorial assistance. YP, CMG, and DP conducted angiographic analysis. CL, AC, CBC, and MK conducted ECG core laboratory analysis. JWH, JM, and MK conducted data analysis. JM conducted statistical analysis. JWH takes responsibility for the paper as a whole.

**Funding and support:** By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflicts of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. The trial was funded by Heartscape, Inc., the makers of the 80-lead technology. The data were collated and analyzed by an independent contract research organization (CCT, Inc.). The steering committee had full control of the study design, and CCT had complete control of the data, without sponsor influence. The authors do not hold stock in the company, although a few have served as consultants to the company in trial design and product development. The authors have had complete access to and control of the data and complete freedom with data analysis and results presentation in this article, without influence from Heartscape.

**Publication dates:** Received for publication April 3, 2009. Revision received June 16, 2009. Accepted for publication June 24, 2009. Available online September 19, 2009.

Reprints not available from the authors.

**Address for correspondence:** James Hoekstra, MD, Department of Emergency Medicine, Wake Forest University Health Sciences, Medical Center Blvd, Winston-Salem, NC 27023; 336-716-4626, fax 336-716-5438; E-mail jhoekstr@wfubmc.edu.

**REFERENCES**


**CORRECTION**

In the July 2009 issue, in the Journal Club (“The Measurement of Reliability,” page 10, table on left in answer 4C), in column 3, row 3, it should have said “4,” not “40.” We apologize for this error.
APPENDIX E1. List of clinical sites.

Duke University Medical Center
Baystate Medical Center
Wake Forest University Baptist Medical Center
William Beaumont Hospital
Columbia University Medical Center
Cleveland Clinic

University of Cincinnati Medical Center
Medical University South Carolina Hospital
Tampa General Hospital
Thomas Jefferson University Hospital
University of California Davis Medical Center
Beth Israel Deaconess Medical Center